Novo Nordisk Sues Eli Lilly Over Deceptive Ads

On July 21, Novo Nordisk filed a lawsuit against Eli Lilly, accusing the company of false and misleading advertising concerning their respective injectable weight-loss medications. Novo Nordisk contends that Eli Lilly's advertisements deliberately present an oversimplified and inaccurate comparison by touting outdated clinical trials. These trials allegedly compare the highest doses of Lilly's drugs to lower doses of Novo Nordisk's medicines, creating a misleading impression of superiority.

Novo Nordisk asserts that these deceptive campaigns have misled consumers, particularly those with obesity and diabetes. The senior vice president and group general counsel for Novo Nordisk stated that the ads lead patients to believe Lilly's drugs are superior. While Novo Nordisk is not seeking to stop the sale of Lilly's medications, it is asking a judge for a permanent order to remove the comparison advertisements across all platforms and to compel Lilly to launch a corrective advertising campaign.

This lawsuit emerges as both pharmaceutical companies fiercely compete in the market for popular GLP-1 weight-loss drugs. Novo's Wegovy was an early entrant, but Lilly's Zepbound has seen significant sales growth, reaching nearly $4.2 billion in the first three months of 2026, an 80% increase year-over-year. The market for weight-loss drugs is projected to reach approximately $100 billion annually within the next decade, with multiple pharmaceutical companies developing new treatments. Both companies may also benefit from a new Medicare pilot program launched on July 1, the Medicare GLP-1 Bridge program, which helps eligible enrollees access prescription weight-loss medications.